A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma-Reference-Cited by-同舟云学术

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

Published:2014-03-26 Issue:13 Volume:120 Page:2016-2024
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hamid Omid¹,Ilaria Robert²,Garbe Claus³,Wolter Pascal⁴,Maio Michele⁵,Hutson Thomas E.⁶,Arance Ana⁷,Lorigan Paul⁸,Lee Jeeyun⁹,Hauschild Axel¹⁰,Mohr Peter¹¹,Hahka-Kemppinen Marjo²,Kaiser Christopher²,Turner P. Kellie²,Conti Ilaria²,Grob Jean-Jacques¹²

Affiliation:

1. The Angeles Clinic and Research Institute; Los Angeles California

2. Eli Lilly and Company; Indianapolis Indiana

3. Center for Dermatooncology of the University of Tuebingen; Tuebingen Germany

4. Department of General Medical Oncology; University Hospitals; Leuven Belgium

5. Medical Oncology and Immunotherapy; University Hospital of Siena; Siena Italy

6. Baylor Charles A. Sammons Cancer Center; Dallas Texas

7. Department of Medical Oncology, Hospital Clinic; Barcelona Spain

8. University of Manchester and Christie NHS Foundation Trust; Manchester United Kingdom

9. Samsung Medical Center; Seoul Korea

10. Department of Dermatology; University Hospital Schleswig-Holstein; Campus Kiel Kiel Germany

11. Elbe Kliniken Stade Buxtehude GmbH; Germany